Navigation Links
ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants
Date:11/18/2007

Board appointments also made

MINNEAPOLIS, Nov. 19 /PRNewswire/ -- At its Board Meeting on Wednesday, November 14, the Board of Directors of ClearWay Minnesota approved 11 grants for new research on topics ranging from the Freedom to Breathe Act's impact on young adults to interventions that reduce tobacco use and secondhand smoke exposure among Chicano Latino youth and African immigrants. ClearWay Minnesota will award more than $2.8 million to Minnesota researchers through these grants, which bring ClearWay Minnesota's total expenditures on competitive research grants to more than $14.5 million since 1998.

"These new grant awards show our continuing commitment to innovative research that shapes our work to reduce tobacco's harm," said David Willoughby, ClearWay Minnesota's Chief Executive Officer. "This significant investment in research will pay healthy dividends for Minnesotans well into the future."

Eleven research grants, totaling $2,828,060, were awarded to:

-- The University of Minnesota Medical School, in collaboration with

Hennepin Family Care East Lake Clinic, to develop a tobacco

intervention for Chicano Latino youth by engaging parents ($89,776);

-- Wilder Research, in collaboration with the Minnesota African Women's

Association, to assess African immigrant women's and girls' exposure

to secondhand smoke by male relatives, and to raise awareness about

tobacco-related risks ($126,440);

-- The University of Minnesota Medical School, in collaboration with La

Creche, for a study on secondhand smoke exposure among lower income,

inner-city, African American parents of young children ($126,863);

-- The University of Minnesota School of Public Health, in collaboration

with Carver County Public Health, to develop and pilot-test a smoking

cessation/occupational health and safety program for manufactur
'/>"/>

SOURCE ClearWay Minnesota
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ClearWay Minnesota(SM) to Share Stories of Real Minnesotans Who Used QUITPLAN(R) Services During Great American Smokeout
2. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
3. Richard Greco Joins Mediware Board
4. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
5. Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers
6. Montana Health Care Leader Elected Board Chair of National Association
7. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
8. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
9. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. Patient Safety Authority Board of Directors Names Infection Advisory Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...suggests more choices need to be available to coup...s) -- A new survey suggests that many American wom...appy with the usual options available for the disp..., Most of 1,020 women surveyed said they were ver...o be thawed and thrown away, used by other women, ...
(Date:12/4/2008)...ogists have discovered a mechanism that is critica..., where a cell divides into two identical daughter...ow on the assembly and activity of a ring of actin...l at just the right time. They focused on key prot...romote the production of both linear and branching...
(Date:12/4/2008)...GELES, Dec. 4 Jessica Biel and fam...liday party held Dec. 2 at the Childrens,Hospital...ake The Difference,Network, included numerous rec...n an effort to bring holiday spirit to children at...umerous activities as well as seeing some of the,...
(Date:12/4/2008)...GTON, Dec. 4 On this I...gainst Women , the Pan American Health and Educati...s Global Violence Prevention project. The project ...mmunity that violence is preventable. , , ...nce Prevention: The Investment that Saves Lives , ...
Breaking Medicine News(10 mins):Health News:Women Unhappy With Disposal Options After Infertility Treatment 2Health News:Women Unhappy With Disposal Options After Infertility Treatment 3Health News:Researchers gain new insight on wonder of cell division 2Health News:Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles 2Health News:PAHEF Works to Prevent Violence Against Women 2
... in India is reported to cause 527,700 deaths a ye... (WHO) study, only China has more number of premat... United States comes a close third. According to ...zation (WHO) report, diseases triggered by indoor ...
...ities have broken off talks with striking doctors ...ter's office for about 20 days to demand higher pa... be no more discussions with the unions, the gover...bigniew Religa, after union representatives walke...
...t The University of Nottingham have just given peo...t smokers lose more muscle mass in old age than no...r dangers posed by smoking such as cancer, heart a...ough earlier research had established that smokers...
...as revealed that individuals age 49 and older with...lated macular degeneration appear to have higher ...without such visual impairments. Several studies ... between visual problems and the risk of death in ...
Other Medicine News:Health News:Air Pollution in India Causes 527,700 Deaths a Year 2Health News:Smoking Speeds Up Muscle Loss 2Health News:Visual Impairment Linked to Greater Mortality Risk 2
(Date:12/4/2008)...PRNewswire-FirstCall/ -- Thoratec Corporation,(Na...hanical circulatory support,therapies to save, su...a,pre-specified interim analysis of data from its...ial shows that patients implanted with the device,...hose in the control group who,were implanted with...
(Date:12/4/2008)... to Advance to Clinical Trials , , SAN DIEG... Inc., a biopharmaceutical company focused on the ...gonists for the treatment of cancer, respiratory a...s initiated a Phase I clinical trial of VTX-2337, ...er. The multi-center clinical trial is being cond...
(Date:12/3/2008)...monstrating potential in newly diagnosed patients ...tured in two oral sessions at ASH , , - Exj...y transfused patients by significantly reducing to...ew long-term data from major independent breast ca...ery treatment strategy, Femara vs. tamoxifen , ...
(Date:12/3/2008)...iates long-term anemia and organ damage in mice an... MEMPHIS, Tenn., Dec. 3 ...e into mouse blood cells, scientists at St. Jude C... cell disease pathology. In their studies, the res...ially no difference from normal mice. Although the...
Breaking Medicine Technology:Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 2Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 3Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial 4VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 1AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 2AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform 3091 3A breakthrough in contrast enhanced intraoperative ultrasonography 26539 1Does probiotic intervention induce the serum global lipid profile change 3F 26535 1Does probiotic intervention induce the serum global lipid profile change 3F 26535 2Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday September 24th 3090 1Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday September 24th 3090 2
...alif.--(BUSINESS WIRE)--Mar 22, 2007 - Aeolus,Phar... successful,completion of the analysis of results ...AEOL 10150 ("Study 102"). The clinical,direction f...th the,most likely targets for an efficacy study a...y in lung cancer and/or head and neck,cancer and A...
...--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma,Cor...developing,drugs for HIV and Multiple Sclerosis ha..., ReceptoPharm, has received notification of,accep... Reviews in,Immunology special conference issue., ...ble therapy,for Multiple Sclerosis; a review of th...
Other Medicine Technology:Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 2Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 3Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
Aplicare's Saturated Swabsticks are packaged in easy open, single-use foil-laminated pouches. Each 4 inch Swabstick is saturated with precisely the correct amount of solution. Each package is termina
Aplicare's saturated swabsticks are packaged in easy open, single use, foil-laminated pouches. Each 4 inch swabstick is saturated with precisely the correct amount of Povidone Iodine gel. The Gel Swa
An Antiseptic Antibacterial that does not contain Alcohol. In less than 30 seconds, destroys over 99% of bacteria. Can be used for cleansing of minor wounds, burns, cuts, scrapes and for disinfection
All Povidone Iodine 'Prep' solutions are effective for skin and mucous membrane preparation prior to surgical procedures. All Povidone Iodine 'Scrub' solutions are antimicrobial solutions with surfac
Medicine Products: